| 15.74 0.46 (3.01%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.97 | 1-year : | 22.16 |
| Resists | First : | 16.25 | Second : | 18.97 |
| Pivot price | 14.88 |
|||
| Supports | First : | 14 |
Second : | 12.61 |
| MAs | MA(5) : | 15.49 |
MA(20) : | 14.71 |
| MA(100) : | 12.54 |
MA(250) : | 8.01 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 75.8 |
D(3) : | 73.5 |
| RSI | RSI(14): 59.9 |
|||
| 52-week | High : | 17.25 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ANL ] has closed below upper band by 19.2%. Bollinger Bands are 12.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.93 - 16.01 | 16.01 - 16.08 |
| Low: | 15.06 - 15.15 | 15.15 - 15.22 |
| Close: | 15.61 - 15.74 | 15.74 - 15.86 |
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Fri, 18 Sep 2026
Adlai Nortye (NASDAQ: ANL) director lines up ADS sale - Stock Titan
Wed, 16 Sep 2026
Adlai Nortye Group Ltd. SEC Filing (Sep 16, 2026) - Stock Titan
Fri, 28 Aug 2026
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Tue, 18 Aug 2026
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
Fri, 14 Aug 2026
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress - GlobeNewswire
Thu, 06 Aug 2026
Adlai Nortye (ANL) Edges Higher: Key Levels to Watch After 1.3% Gain - Buyback Factor - CarePlus VietNam
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 45.2 (%) |
| Shares Short | 4,300 (K) |
| Shares Short P.Month | 3,520 (K) |
| EPS | -0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.33 |
| Profit Margin | -124.8 % |
| Operating Margin | -44.2 % |
| Return on Assets (ttm) | -8.7 % |
| Return on Equity (ttm) | -20.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.3 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -23.85 |
| PEG Ratio | 0 |
| Price to Book value | 4.71 |
| Price to Sales | 51.18 |
| Price to Cash Flow | -27.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|